Yuxuan Liu1, Yulissa Gonzalez1, Jennifer E Amengual2. 1. Division of Hematology and Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA. 2. Division of Hematology and Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA. Jea2149@columbia.edu.
Abstract
PURPOSE OF REVIEW: Emerging evidence has shown that epigenetic derangements might drive and promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. The purpose of this review is to explain how the epigenetic derangements result in a chromatin-remodeled state in lymphoma and contribute to the biology and clinical features of these tumors. RECENT FINDINGS: Studies have explored on the functional role of epigenetic derangements in chromatin remodeling and lymphomagenesis. For example, the haploinsufficiency of CREBBP facilitates malignant transformation in mice and directly implicates the importance to re-establish the physiologic acetylation level. New findings identified 4 prominent DLBCL subtypes, including EZB-GC-DLBCL subtype that enriched in mutations of CREBBP, EP300, KMT2D, and SWI/SNF complex genes. EZB subtype has a worse prognosis than other GCB-tumors. Moreover, the action of the histone modifiers as well as chromatin-remodeling factors (e.g., SWI/SNF complex) cooperates to influence the chromatin state resulting in transcription repression. Drugs that alter the epigenetic landscape have been approved in T cell lymphoma. In line with this finding, epigenetic lesions in histone modifiers have recently been uncovered in this disease, further confirming the vulnerability to the therapies targeting epigenetic derangements. Modulating the chromatin state by epigenetic-modifying agents provides precision-medicine opportunities to patients with lymphomas that depend on this biology.
PURPOSE OF REVIEW: Emerging evidence has shown that epigenetic derangements might drive and promote tumorigenesis in various types of malignancies and is prevalent in both B cell and T cell lymphomas. The purpose of this review is to explain how the epigenetic derangements result in a chromatin-remodeled state in lymphoma and contribute to the biology and clinical features of these tumors. RECENT FINDINGS: Studies have explored on the functional role of epigenetic derangements in chromatin remodeling and lymphomagenesis. For example, the haploinsufficiency of CREBBP facilitates malignant transformation in mice and directly implicates the importance to re-establish the physiologic acetylation level. New findings identified 4 prominent DLBCL subtypes, including EZB-GC-DLBCL subtype that enriched in mutations of CREBBP, EP300, KMT2D, and SWI/SNF complex genes. EZB subtype has a worse prognosis than other GCB-tumors. Moreover, the action of the histone modifiers as well as chromatin-remodeling factors (e.g., SWI/SNF complex) cooperates to influence the chromatin state resulting in transcription repression. Drugs that alter the epigenetic landscape have been approved in T cell lymphoma. In line with this finding, epigenetic lesions in histone modifiers have recently been uncovered in this disease, further confirming the vulnerability to the therapies targeting epigenetic derangements. Modulating the chromatin state by epigenetic-modifying agents provides precision-medicine opportunities to patients with lymphomas that depend on this biology.
Authors: Kilannin Krysiak; Felicia Gomez; Brian S White; Matthew Matlock; Christopher A Miller; Lee Trani; Catrina C Fronick; Robert S Fulton; Friederike Kreisel; Amanda F Cashen; Kenneth R Carson; Melissa M Berrien-Elliott; Nancy L Bartlett; Malachi Griffith; Obi L Griffith; Todd A Fehniger Journal: Blood Date: 2016-11-14 Impact factor: 22.113
Authors: Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes Journal: Hum Mutat Date: 2008-05 Impact factor: 4.878
Authors: Jennifer K Lue; Sathyen A Prabhu; Yuxuan Liu; Yulissa Gonzalez; Akanksha Verma; Prabhjot S Mundi; Nebiyu Abshiru; Jeannie M Camarillo; Swasti Mehta; Emily I Chen; Changhong Qiao; Renu Nandakumar; Serge Cremers; Neil L Kelleher; Olivier Elemento; Jennifer E Amengual Journal: Clin Cancer Res Date: 2019-04-12 Impact factor: 13.801
Authors: J H Schatz; S M Horwitz; J Teruya-Feldstein; M A Lunning; A Viale; K Huberman; N D Socci; N Lailler; A Heguy; I Dolgalev; J C Migliacci; M Pirun; M L Palomba; D M Weinstock; H-G Wendel Journal: Leukemia Date: 2014-09-03 Impact factor: 11.528